2022
Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
Simader FA, Howard JP, Ahmad Y, Saleh K, Naraen A, Samways JW, Mohal J, Reddy RK, Kaza N, Keene D, Shun-Shin MJ, Francis DP, Whinnett ZI, Arnold AD. Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. EP Europace 2022, 25: 341-350. PMID: 36305545, PMCID: PMC9934993, DOI: 10.1093/europace/euac173.Peer-Reviewed Original ResearchConceptsHeart failure hospitalizationCatheter ablationHeart failureMedical therapyFailure hospitalizationAtrial fibrillationCardiovascular outcomesPrimary analysisPre-specified primary endpointAtrial fibrillation catheter ablationCause mortalityPrimary endpointSecondary endpointsLower riskPatientsTherapyHospitalizationFibrillationTrialsMortalityLow heterogeneityAblationEndpointOutcomesFailure
2012
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation
Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Review Of Cardiovascular Therapy 2012, 10: 1471-1480. PMID: 23253272, DOI: 10.1586/erc.12.148.Peer-Reviewed Original ResearchConceptsNew oral anticoagulantsParoxysmal atrial fibrillationOral anticoagulantsNonparoxysmal atrial fibrillationAtrial fibrillationHeart failureStroke preventionNew anticoagulantsContemporary phase III trialsAdditional prognostic benefitPhase III trialsPresence of diabetesNew drugsImpact of genderIII trialsPrognostic benefitDiabetes mellitusAnticoagulantsPatientsWarfarinEvent ratesCardiovascular medicineFibrillationMellitusDiabetesStroke Prevention in Atrial Fibrillation: Concepts and Controversies
Ahmad Y, Lip G. Stroke Prevention in Atrial Fibrillation: Concepts and Controversies. Current Cardiology Reviews 2012, 8: 290-301. PMID: 22920480, PMCID: PMC3492813, DOI: 10.2174/157340312803760820.Peer-Reviewed Original ResearchConceptsStroke risk factorsAtrial fibrillationOral anticoagulationStroke preventionRisk factorsPatient riskIndependent stroke risk factorNew oral anticoagulantsCommon cardiac rhythm disorderLow-risk patientsCardiac rhythm disordersAntiplatelet therapyAntithrombotic therapyOral anticoagulantsSevere strokePerioperative managementEffective therapyRhythm disordersEfficacious agentsGeneral populationNew agentsSimple scorePatientsAnticoagulationFibrillationDabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance
Ahmad Y, Lip GY. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. Heart 2012, 98: 1404. PMID: 22698856, DOI: 10.1136/heartjnl-2012-302101.Peer-Reviewed Original ResearchStroke Prevention in Atrial Fibrillation: Where are We Now?
Ahmad Y, Lip GY. Stroke Prevention in Atrial Fibrillation: Where are We Now? Clinical Medicine Insights Cardiology 2012, 6: cmc.s8976. PMID: 22408371, PMCID: PMC3296491, DOI: 10.4137/cmc.s8976.Peer-Reviewed Original ResearchStroke preventionAtrial fibrillationOnly successful therapyLow-risk patientsBetter risk stratificationStroke prophylaxisRisk stratificationCommon arrhythmiaNovel anticoagulantsSuccessful therapyWarfarinPatientsGreater mortalityPreventionFibrillationAF researchEffective alternativeNew optionsAnticoagulationImproved management strategiesProphylaxisAnticoagulantsArrhythmiasTherapyMajor progress